ArticleFrontiers in psychiatry2025
Association between olanzapine and immune function in lung cancer patients with anxiety and depression: a retrospective cohort study of medical records.
Article in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anxiety and depression are prevalent in cancer patients and often impair immune function, compromising antitumor responses. Anti-anxiety medications, such as olanzapine, show promise in alleviating psychological distress, potentially enhancing immune function in patients with malignant tumors. Objective: This study aims to investigate immunological alterations in lung cancer patients with anxiety and depression and evaluate the immunomodulatory effects of olanzapine in this population. Methods: We retrospectively analyzed data from 179 oncology patients at a single center. Of these, 38 lung cancer patients served as the control group, while 33 lung cancer patients, admitted under standard hospital conditions, received olanzapine therapy (treatment group) during hospitalization. We monitored complete blood count, blood biochemistry, and lymphocyte subsets (CD3, CD4, CD8, NK cells, B lymphocytes). Anxiety and depression were assessed using the Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS). Results: Lung cancer patients with concurrent anxiety and depression exhibited elevated CD3, CD4, CD8, NK cell counts, and CD4/CD8 ratio, alongside reduced Neutrophil-to-Lymphocyte Ratio (NLR) (P = 0.044, 0.001, 0.022, 0.039, 0.007, 0.003). Those with both conditions had lower serum albumin compared to patients with depression alone (P = 0.016) or either condition independently (P = 0.015). Patients with anxiety and depression showed reduced CD3, CD8, and NK cell counts compared to those with single conditions (P = 0.005, 0.037, 0.018). Baseline SAS/SDS scores showed no significant differences between groups (P = 0.385, 0.603). Olanzapine treatment significantly increased CD3, CD4, and NK cell counts (P = 0.001 each), reduced NLR and B lymphocytes (P<0.001, 0.036), and elevated HDL cholesterol (P = 0.014) compared to controls. Post-treatment, the treatment group's SDS scores decreased from 42.64 ± 6.32 to 37.06 ± 8.34 (P<0.001), and SAS scores dropped from 50.48 ± 12.94 to 43.61 ± 13.47 (P<0.001). Conclusion: Anxiety and depression impair immune function in lung cancer patients, while olanzapine enhances CD3, CD4, and NK cell activity and reduces psychological distress, suggesting its potential as an adjunct in cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.